AI Summary

A study of early‑stage multiple sclerosis found that therapies targeting immune B cells reduced disease activity more effectively than commonly prescribed oral drugs. Patients receiving intravenous B‑cell‑depleting agents experienced a 62 % lower relapse rate compared with those taking pills. The researchers also observed that initiating B‑cell‑depleting treatment shortly after diagnosis was linked to a reduced likelihood of developing brain scarring associated with MS. These findings suggest that early use of B‑cell‑targeted IV therapy may better control relapse risk and neuro‑degeneration in newly diagnosed patients.

AI summaries can be wrong sometimes—always verify important details using the source article.